Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The effectiveness of a vaccine can be improved by using a "prime boost strategy" or by using
an adjuvant. A prime boost strategy is the administration of one type of vaccine (the primer)
followed by the administration of another type vaccine (the booster). An adjuvant is a
substance that can enhance the immune response when given at the same time as a vaccine.
This study will evaluate the safety of and immune response to a vaccine designed to be used
as part of a prime boost strategy. The study will also evaluate the vaccine when given with
an adjuvant. The vaccine in this study is not produced from live HIV or from infected cells.
It does not contain HIV, and it cannot cause HIV infection.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)